Plasmodium vivax malaria

This trial tests different doses of tafenoquine, a single-dose drug, to see if it can effectively cure Plasmodium vivax malaria by targeting dormant liver stages. The study involves 820 people in Southeast Asia with confirmed vivax malaria. Researchers aim to find a dose that pre…

This study at the National Institutes of Health evaluates and treats people aged 3 and older with known or suspected parasitic infections, such as malaria, intestinal worms, and others. Participants receive standard medical care, not experimental treatments. The goal is to monito…

This study tests a new way to find and treat a type of malaria (P. vivax) that can hide in the liver and come back months later. Researchers will use a simple blood test to find people who have been infected recently, then give them a treatment to clear the hidden parasites. The …

This study tests a single dose of tafenoquine in 30 children in Papua New Guinea who have vivax malaria. The goal is to see how the drug moves through the body and if it is safe. Vivax malaria can come back because it hides in the liver, and this drug aims to clear it completely.

This study looks at how safe and effective primaquine is for treating vivax malaria in people with intermediate or deficient G6PD enzyme levels. About 100 adults with confirmed malaria and G6PD deficiency will receive either a high daily dose or a weekly dose of primaquine. The g…

This study will give a combination of two malaria drugs (dihydroartemisinin-piperaquine and primaquine) to entire communities in Ghana every two months for two years. The goal is to see if this approach can reduce the number of people carrying malaria parasites, even those with n…

This study is checking how effective the R21/Matrix-M malaria vaccine is at protecting children under 5 in Burkina Faso and Uganda, where malaria is common. Researchers will compare vaccination history in children who test positive for malaria against those who test negative. The…

This study tests whether giving anti-malarial drugs to everyone in a village can eliminate vivax malaria. Over 7,500 people in Peru will be split into two groups: one receiving standard care (bed nets, screening) and the other also receiving mass drug administration. The goal is …

This study gives healthy adults a controlled malaria infection using donated blood containing the P. vivax parasite. Researchers will monitor how the infection develops, how the immune system responds, and whether mosquitoes can pick up the parasite from participants. The goal is…

This study aims to find the smallest number of infected mosquito bites needed to give healthy adults malaria. Twenty-four volunteers will be bitten by 1, 2, or 3 mosquitoes carrying the Plasmodium vivax parasite. The results will help researchers develop better ways to test futur…

This study aims to safely give healthy Thai adults a controlled malaria infection using frozen infected blood cells. Researchers will monitor participants closely in a hospital to find the best dose for future studies. The goal is to learn more about the malaria parasite and help…